Adenosine receptors and b-adrenoceptors are G-protein-coupled receptors (GPCRs) that activate intracellular G proteins on binding the agonists adenosine 1 or noradrenaline 2 , respectively. GPCRs have similar structures consisting of seven transmembrane helices that contain well-conserved sequence motifs, indicating that they are probably activated by a common mechanism 3,4 . Recent structures of b-adrenoceptors highlight residues in transmembrane region 5 that initially bind specifically to agonists rather than to antagonists, indicating that these residues have an important role in agonist-induced activation of receptors 5-7 . Here we present two crystal structures of the thermostabilized human adenosine A 2A receptor (A 2A R-GL31) bound to its endogenous agonist adenosine and the synthetic agonist NECA. The structures represent an intermediate conformation between the inactive and active states, because they share all the features of GPCRs that are thought to be in a fully activated state, except that the cytoplasmic end of transmembrane helix 6 partially occludes the G-protein-binding site. The adenine substituent of the agonists binds in a similar fashion to the chemically related region of the inverse agonist ZM241385 (ref. 8). Both agonists contain a ribose group, not found in ZM241385, which extends deep into the ligand-binding pocket where it makes polar interactions with conserved residues in H7 (Ser 277 7.42 and His 278 7.43 ; superscripts refer to Ballesteros-Weinstein numbering 9 ) and non-polar interactions with residues in H3. In contrast, the inverse agonist ZM241385 does not interact with any of these residues and comparison with the agonist-bound structures indicates that ZM241385 sterically prevents the conformational change in H5 and therefore it acts as an inverse agonist. Comparison of the agonist-bound structures of A 2A R with the agonist-bound structures of b-adrenoceptors indicates that the contraction of the ligand-binding pocket caused by the inward motion of helices 3, 5 and 7 may be a common feature in the activation of all GPCRs.
Adenosine receptors and b-adrenoceptors are G-protein-coupled receptors (GPCRs) that activate intracellular G proteins on binding the agonists adenosine 1 or noradrenaline 2 , respectively. GPCRs have similar structures consisting of seven transmembrane helices that contain well-conserved sequence motifs, indicating that they are probably activated by a common mechanism 3, 4 . Recent structures of b-adrenoceptors highlight residues in transmembrane region 5 that initially bind specifically to agonists rather than to antagonists, indicating that these residues have an important role in agonist-induced activation of receptors [5] [6] [7] . Here we present two crystal structures of the thermostabilized human adenosine A 2A receptor (A 2A R-GL31) bound to its endogenous agonist adenosine and the synthetic agonist NECA. The structures represent an intermediate conformation between the inactive and active states, because they share all the features of GPCRs that are thought to be in a fully activated state, except that the cytoplasmic end of transmembrane helix 6 partially occludes the G-protein-binding site. The adenine substituent of the agonists binds in a similar fashion to the chemically related region of the inverse agonist ZM241385 (ref. 8) . Both agonists contain a ribose group, not found in ZM241385, which extends deep into the ligand-binding pocket where it makes polar interactions with conserved residues in H7 (Ser 277 7.42 and His 278 7.43 ; superscripts refer to Ballesteros-Weinstein numbering 9 ) and non-polar interactions with residues in H3. In contrast, the inverse agonist ZM241385 does not interact with any of these residues and comparison with the agonist-bound structures indicates that ZM241385 sterically prevents the conformational change in H5 and therefore it acts as an inverse agonist. Comparison of the agonist-bound structures of A 2A R with the agonist-bound structures of b-adrenoceptors indicates that the contraction of the ligand-binding pocket caused by the inward motion of helices 3, 5 and 7 may be a common feature in the activation of all GPCRs.
In the simplest model for the conformational dynamics of GPCRs 10 there is an equilibrium between two states, R and R*. The inactive state R preferentially binds inverse agonists and the activated state R* preferentially binds agonists 11 . Only R* can couple and activate G proteins. Although there are far more complex schemes 12 describing intermediates between R and R*, studies on rhodopsin have indicated that there is only one major conformational change that significantly alters the structure of the receptor 3 . Thus the structures of dark-state rhodopsin 13, 14 and of opsin 15, 16 are considered to be representative structures for the R and R* state, respectively. Structures of six different GPCRs 8,13,17-21 in conformations closely approximating the R state have now been determined and it is clear that they are similar to each other, with root mean squared deviation (r.m.s.d.) between any pair of structures in the transmembrane domains being less than 3 Å . As observed in light activation of rhodopsin, the major structural difference between R and R* is the movement of the cytoplasmic ends of helices 5 and 6 away from the receptor core by 5-6 Å , opening up a cleft in the centre of the helix bundle where the carboxy terminus of a G protein can bind 16 . Recently, the structure of an agonist-bound b-adrenoceptor (b 2 -AR) was determined in complex with an antibody fragment (nanobody Nb80) 5 . This structure of b 2 -AR is very similar to the structure of opsin, which indicates that the nanobody mimicked the action of a G protein by maintaining the receptor structure in an activated state. Given the structural similarities between opsin and the b 2 -AR-Nb80 complex, it is likely that the structures of the R* states of other GPCRs are also highly similar. This is consistent with the same heterotrimeric G proteins being able to couple to multiple different receptors 22 . However, it is unclear whether conserved structures of R and R* indicate that all agonists activate the receptors in an identical fashion. The recent structures of a thermostabilized b 1 -AR bound to four different agonists indicated that a defining feature of agonist binding to this receptor is the formation of a hydrogen bond with Ser 5.46 on transmembrane helix 5 that accompanies the contraction of the ligand-binding pocket 7 . Here we describe two structures of the adenosine A 2A receptor (A 2A R) bound to two different agonists, which indicates that the initial action of agonist binding to A 2A R has both similarities and differences compared to agonist binding in b-ARs.
The native human A 2A R when bound to its endogenous agonist adenosine or to the high-affinity synthetic agonist NECA is unstable in detergent, so crystallization and structure determination relied on using a thermostabilized construct (A 2A R-GL31) that contained four point mutations, which markedly improved its thermostability. Pharmacological analysis showed that the mutant receptor bound the five antagonists tested with greatly reduced affinity (1.8-4.3 log units), whereas four agonists bound with similar affinity to the wildtype receptor ( Supplementary Fig. 1 ). However, A 2A R-GL31 is only weakly activated by the agonist CGS21680 ( Supplementary Fig. 2 ), which indicates that the thermostabilizing mutations might also decouple high-affinity agonist binding from the formation of R*. The conformation of A 2A R-GL31 is not consistent with it being in the fully activated G-protein-coupled state, because we do not observe a 42-fold increase in affinity for NECA binding measured for G ascoupled A 2A R (ref. 23) . These data all indicate that A 2A R-GL31 is in an intermediate conformation between R and R*, which is consistent with the structural analysis presented later.
The two structures we have determined are of A 2A R-GL31 bound to adenosine and NECA with resolutions of 3.0 Å and 2.6 Å , respectively (Supplementary Table 1 ). Global alignments of the A 2A R-GL31 structures with A 2A -T4L (A 2A R with T4 lysozyme inserted into inner loop 3) bound to the inverse agonist ZM241385 were performed based on those residues in the region of the ligand-binding pocket that show the closest structural homology ( Fig. 1 and Supplementary Text). This gave an r.m.s.d. in Ca positions of 0.66 Å for the 96 atoms selected, which include all residues involved in binding either adenosine or NECA, with the exception of those in H3. Using this transformation, the adenine-like moiety of the two ligands superimposes almost exactly (r.m.s.d. 0.56 Å ). The most significant differences between the two structures are seen in a distortion and a 2 Å shift primarily along the helical axis of H3, a bulge in H5 (resulting from non-helical backbone conformation angles of residues Cys 185 and Val 186) that shifts residues into the binding pocket by up to 2 Å and also a change in conformation of the cytoplasmic ends of H5, H6 and H7 ( Fig. 1) . Comparison of the A 2A R-GL31 structure with the agonist-bound b 2 -AR-Nb80 complex indicates that these differences are similar to the conformational changes in the b 2 -AR that are proposed to be responsible for the formation of the R* state 5 . However, it is unlikely that the structure of A 2A R-GL31 represents the fully activated state, because comparison with opsin bound to the C-terminal peptide of the G protein transducin shows that there is insufficient space in A 2A R-GL31 for the C terminus of the G protein to bind ( Supplementary Fig. 3 ). This is on the basis of the assumption that all G proteins bind and activate GPCRs in a similar fashion, but given the highly conserved structures of both G proteins and GPCRs this seems a reasonable hypothesis.
The fact that the structure of A 2A R-GL31 represents an agonistbinding state is consistent with how A 2A R-GL31 was engineered. Thermostabilizing mutations were selected by heating the NECAbound detergent-solubilised receptor, so the mutations are anticipated to stabilize the agonist-bound state either by stabilizing helix-helix interactions and/or biasing the conformational equilibrium between the agonist-bound R* state and the agonist-bound R state [24] [25] [26] . The two most thermostabilizing mutations, L48A and Q89A, are in regions of the receptor that are involved in transitions between R and R*, providing a possible explanation for their thermostabilizing effect (Supplementary Fig. 4 ). The other two mutations, A54L and T65A, are at the receptor-lipid interface and the reason for their thermostabilizing effect is unclear. Although the overall shape of the ligand-binding pockets of A 2A R and b 2 AR are different, the structural similarities with the b 2 -AR-Nb80 (ref. 5) and the structural differences to ZM241385bound A 2A -T4L 8 indicate that the structure of the binding pocket in A 2A R-GL31 is a good representation of the agonist-bound binding pocket of the wild-type receptor ( Fig. 1 ).
Adenosine and NECA bind to A 2A R-GL31 in a virtually identical fashion; in addition, the adenine ring in the agonists interacts with A 2A R in a similar way to the chemically related triazolotriazine ring of the inverse agonist ZM241385 (Fig. 2) . Thus the hydrogen bonds between exocyclic adenosine N6 ( Supplementary Fig. 5 ) with both Glu 169 in extracellular loop 2 (EL2) and Asn 253 6.55 in H6 are similar, with the significant p-stacking interaction with Phe 168 in EL2 also conserved. One of the major structural differences between ZM241385 and the agonists is the presence of a furan substituent on C20 of triazolotriazine in the inverse agonist, whereas agonists contain a ribose substituent linked to N9 of adenine ( Fig. 2 and Supplementary Fig. 5 ). In ZM241385, the furan group forms a hydrogen bond with Asn 253 6.55 in H6 and van der Waals contacts with other residues in H3, H5 and H6 (ref. 8) . In contrast, the ribose moiety in agonists forms hydrogen bonds with Ser 277 7.42 and His 278 7.43 in H7, in addition to van der Waals interactions with other residues in H3 and H6 (Fig. 2 ). In particular, Val 84 3.32 has to shift its position upon agonist binding owing to a steric clash with the ribose ring, which may contribute to the 2 Å shift observed in H3 ( Fig. 3 ). These differences in binding between ZM241385 and either adenosine or NECA indicate that the residues that bind uniquely to agonists (Ser 277 7.42 and His 278 7.43 ) have a key role in the activation of the receptor, as previously shown by mutagenesis studies 27, 28 . This is analogous to the situation in the activation of b 1 -AR, where only full agonists cause the rotamer conformation changes of Ser 5.46 in H5, whereas the inverse agonist ICI118551 prevents receptor activation by sterically blocking the rotamer change 7, 29 . However, the details of the activation differ in that the critical residues that bind agonists and not antagonists are in H5 in the b 1 -AR, but in H7 in the A 2A R (Fig. 4 ).
Adenosine and NECA activate the A 2A R through interactions with H3 and H7 that are absent in the interactions between the receptor and the inverse agonist ZM241385 (Fig. 2) . The inward shift of H7, the movement of H3 and the consequent formation of a bulge in H5 are all observed in the structures of agonist-bound A 2A R-GL31 and b 2 -AR-Nb80 (Fig. 1) . The formation of the bulge in H5 of the b 2 -AR-Nb80 structure was linked to a series of conformational changes that generate the 60u rotation of H6 about Phe 282 6.44 , resulting in the cytoplasmic end of H6 moving out from the receptor centre and opening the cleft where the C terminus of a G protein is predicted to bind as observed in opsin 5, 6 . There are analogous side-chain movements in A 2A R-GL31 Analogous alignments to opsin are depicted in Supplementary Fig. 7 .
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that result in a 40u rotation of H6, but the cytoplasmic end of H6 remains partially occluding the G-protein-binding cleft (Supplementary Fig. 3 ), perhaps because the fully active conformation requires the binding of G proteins to stabilize it. Interestingly, the structure of b 2 -AR 6 with a covalently bound agonist is also not in the fully activated R* conformation, which is only seen after the nanobody Nb80 is bound 5 . The importance of the bulge in H5 in the activation of A 2A R is highlighted by how inverse agonists bind. Formation of the H5 bulge results in the inward movement of Cys 185 5.46 (Cb moves by 4 Å ), which in turn causes the movement of Val 186 and ultimately a shift of His 250 6.52 by 2 Å into the ligand-binding pocket, thereby sterically blocking the binding of ZM241385 ( Supplementary Fig. 4 ). Hence, when the inverse agonist binds, it is anticipated that the H5 bulge is unlikely to form owing to the opposite series of events and hence the formation of the R* state is inhibited. Thus, in both b-ARs and A 2A R, the formation of the G5 bulge seems to be a common action of agonists, whereas inverse agonists seem to prevent its formation. However, the energetic contributions to its formation may be different between the two receptors. In b-ARs there is a major contribution from direct interaction between the agonist and Ser 5.46 , whereas in A 2A Rs, the major interaction seems to come from Supplementary Fig. 6 and densities for water molecules in Supplementary Fig. 8 . 
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interactions between the agonist and H3, combined with polar interactions involving residues in H7. Despite these differences, agonist binding to both receptors involves strong attractive non-covalent interactions that pull the extracellular ends of H3, H5 and H7 together, which is the necessary prerequisite to receptor activation. While this manuscript was in review, a related manuscript appeared 30 , describing the structure of the A 2A -T4L chimaera bound to the agonist UK432097, which is identical to NECA except for two large substituents on the adenine ring. The structure of UK432097bound A 2A -T4L is very similar to the structures presented here in the transmembrane regions (r.m.s.d. 0.6 Å ), although there are differences in the extracellular surface due to the bulky extensions of UK432097 interacting with the extracellular loops and the absence of density for residues 149-157. Xu et al. 30 conclude that the structure of UK432097bound A 2A -T4L is in an ''active state configuration'', whereas we conclude that the NECA-and adenosine-bound structures are best defined as representing an intermediate state between R and R*.
METHODS SUMMARY
Expression, purification and crystallization. The thermostabilized A 2A R-GL31 construct contains amino acid residues 1-316 of the human A 2A R, four thermostabilizing point mutations (L48A 2.46 , A54L 2.52 , T65A 2.63 and Q89A 3.37 ) and the mutation N154A to remove a potential N-glycosylation site. A 2A R-GL31 was expressed in insect cells using the baculovirus expression system and purified in the detergent octylthioglucoside using Ni 21 -NTA affinity chromatography and size exclusion chromatography (see Methods). The purified receptor was crystallized in the presence of cholesteryl hemisuccinate by vapour diffusion, under conditions described in Methods. Data collection, structure solution and refinement. Diffraction data were collected in multiple wedges (20u per wedge) from a single cryo-cooled crystal (100 K) for the GL31-NECA complex at beamline ID23-2 at the European Synchrotron Radiation Facility and from four crystals for the GL31-adenosine complex, at beamline I24 at the Diamond Light Source. The structures were solved by molecular replacement using the ZM241385-bound A 2A -T4L structure (PDB code 3EML) 8 as a model (see Methods). Data collection and refinement statistics are presented in Supplementary Table 1 and omit densities for the ligands are shown in Supplementary Fig. 6 . 7 were aligned by superimposing equivalent atoms in the protein structure and the positions of both ligands are shown as stick models with the carbon atoms in blue/green (isoprenaline) or yellow (adenosine); N, blue; O, red. The A 2A R structure is shown, with H5 and H7 as space-filling models (C, grey; N, blue; O, red) and the remainder of the structure as a cartoon (pale green). Some water molecules are shown as red spheres, hydrogen bonds as red dashed lines and the polar contacts as blue dashed lines. The orientation of the figure is identical to that shown in Fig. 2 . b, Structure of the A 2A R bound to adenosine viewed from the extracellular surface. c, Structure of b 1 -AR bound to isoprenaline (PDB code 2Y03) 7 viewed from the extracellular surface. In panels b and c, equivalent side chains in the respective structures that make contacts to both isoprenaline and adenosine in their respective receptors are shown as space-filling models and they have the following Ballesteros-Weinstein numbers (amino acid side chains are shown in parentheses for the A 2A R and b 1 -AR, respectively): 3.32 (V84, D121); 3.36 (T88, V125); 5.42 (N181*, S211); 6.51 (L249, F306); 6.55 (N253, N310); 6.52 (H250*, F307); 7.39 (I274, N329); 7.43 (H278, Y333). An asterisk indicates residues that only make indirect contacts to the agonists via a water molecule.
RESEARCH LETTER

METHODS
Expression, purification and crystallization. The human A 2A construct, GL31, contains four thermostabilizing point mutations (L48A 2.46 , A54L 2.52 , T65A 2.63 and Q89A 3.37 ), the mutation N154A to remove the potential N-glycosylation site and a truncation at the C terminus after Ala 316 (ref. 32) . A polyhistidine tag (His 10 ) was engineered at the C terminus, separated from the receptor by a TEV protease cleavage site. Baculovirus expression and membrane preparation were performed as described previously for the b 1 -AR 33 .
Membranes were thawed at room temperature (20-25 uC) , diluted with 25 mM HEPES pH 7.4, in the presence of protease inhibitors (Complete; Boehringer). Membranes were pre-incubated with NECA at 100 mM for 45 min at room temperature. The receptor-ligand complexes were then solubilised by adding decylmaltoside (DM) and NaCl to give final concentrations of 1.5% and 0.3 M, respectively, stirred for 30 min (4 uC) and insoluble material removed by ultracentrifugation (120,000g, 45min, 4uC). All protein purification steps were performed at 4 uC. The solubilised receptor sample was filtered through a 0.22 mm filter (Millipore) and applied to a 5 ml Ni-NTA superflow cartridge (Qiagen) pre-equilibrated with buffer (25 mM HEPES, pH 7.4, 0.1 M NaCl, 100 mM NECA, 0.15% DM, 2.5 mM imidazole). The column was washed sequentially with the same buffer supplemented with either 10, 40 or 80 mM imidazole, and then eluted with 250 mM imidazole. The eluted receptor-ligand complex was mixed with His 6 -tagged TEV protease to cleave the tag for 4-6 h, 4 uC, concentrated to 2 ml using an Amicon-ultra spin concentrator (Ultracel-50K, Millipore) and then imidazole was removed using a PD-10 column (GE Healthcare). Eluted fractions were further purified by binding the TEV and other contaminants to Ni-NTA (QIAGEN) pre-equilibrated in 25 mM HEPES pH 7.4, 0.1 M NaCl, 100 mM NECA, 0.15% DM, 40 mM imidazole, incubating for 30 min and then collecting the flow-through. For detergent exchange into 0.35% octylthioglucoside (OTG), the sample was concentrated using an Amicon-ultra concentrator (Ultracel-50K, Millipore), diluted tenfold in 25 mM HEPES pH 7.4, 0.1 M NaCl, 100 mM NECA, 0.35% OTG, and concentrated again to 0.3 ml. The protein sample was applied to a Superdex 200 10/300 GL size-exclusion column pre-equilibrated in 25 mM HEPES pH 7.4, 0.1 M NaCl, 100 mM NECA, 0.35% OTG and run at 0.5 ml min 21 . Eluted receptor fractions (2-2.5 ml) were concentrated to 50-60 ml. Protein determination was performed using the amido black 34 assay.
Before crystallization, cholesteryl hemisuccinate (CHS) and OTG were added to 1 mg ml 21 and 0.5% respectively and the protein concentration adjusted to 10-12.5 mg ml 21 . NECA and adenosine A 2A -GL31 crystal hits were obtained using a new PEG-based crystallization screen developed in house 35 . Crystals were grown at 4 uC in 100 nl sitting drops using 0.05 M ADA NaOH, pH 6.4, 23.6% PEG 400, 4% v/v 2-propanol for the NECA complex. Crystals were cryoprotected by soaking in 0.05 M ADA NaOH, pH 6.4, 45% PEG 400. For the adenosine complex, crystals were initially grown in 0.05 M TrisHCl, pH 7.6, 9.6% PEG 200, 22.9%. PEG 300. Crystals were cryoprotected by soaking in 0.05 M TrisHCl, pH 7.5, 15% PEG 200, 30% PEG 300. The crystals were mounted on Hampton CrystalCap HT loops and cryo-cooled in liquid nitrogen. Data collection, structure solution and refinement. Diffraction data for the NECA complex were collected at the European Synchrotron Radiation Facility with a Mar 225 CCD detector on the microfocus beamline ID23-2 (wavelength, 0.8726 Å ) using a 10 mm focused beam and for the adenosine complex on beamline I24 at the Diamond Light Source with a Pilatus 6M detector and a 10 mm microfocus beam (wavelength 0.9778 Å ). The microfocus beam was essential for the location of the best diffracting parts of single crystals, as well as allowing several wedges to be collected from different positions. Images were processed with MOSFLM 36 and SCALA 37 . The NECA complex was solved by molecular replacement with PHASER 38 using the A 2A -T4L structure (PDB code 3EML) 8 as a model after removal of the coordinates for T4L, all solvent molecules and the inverse agonist ZM241384. This structure was then used as a starting model for the structure solution of the adenosine complex. Refinement and rebuilding were carried out with REFMAC5 39 and COOT 40 , respectively. In the final models, 98.1% of residues were in the favoured region of the Ramachandran plot with one outlier for the NECA complex, and 97.7% with no outliers for the adenosine complex. Smile strings for NECA and adenosine were created using Sketcher and dictionary entries using Libcheck. Hydrogen bond assignments for the ligands were determined using HBPLUS 41 .
To facilitate a structural comparison between ZM241385-bound A 2A -T4L and the thermostabilized A 2A -GL31 with bound agonist, the structures were superimposed based on those residues in the region of the ligand-binding pocket that show the closest structural homology. This was achieved using the lsq_improve option of program O 42 and an initial transformation based on residues at the C terminus of helix 6 and the N terminus of helix 7. The final superposition, based on residues 16-21 in H1, 51-70 in H2 and ECL1, 132-140 in H4 and ECL2, 142-146 in ECL2, 166-182 in ECL2 and H5 and 245-283 in H6, ECL3 and H7, gave an r.m.s.d. in Ca positions of 0.66 Å for the 96 atoms and includes almost all residues involved in binding either ligand with the exception of those in H3. Using this transformation, the
